PRP for Thin Endometrium: Does It Work?

A persistently thin endometrial lining is one of the most frustrating problems in IVF — not because it is common (it affects approximately 3 to 5% of IVF cycles) but because standard solutions are limited, and a thin lining below 7 mm is associated with dramatically reduced implantation rates. When oestrogen optimisation, sildenafil, aspirin, and other standard approaches have failed, intrauterine platelet-rich plasma (PRP) infusion has emerged as a promising adjunctive option.

This article explains the rationale for intrauterine PRP, what the evidence currently shows, who is an appropriate candidate, and what the procedure involves.

Why the Endometrium Matters

The endometrium — the inner lining of the uterus — is where embryo implantation must occur. For implantation to succeed, the endometrium needs to be adequately thick (typically at least 7 mm, ideally 8 to 12 mm), correctly structured (trilaminar or triple-layer appearance on ultrasound), and biologically receptive — expressing the right molecular signals during the implantation window.

In a minority of women, the endometrium consistently fails to reach adequate thickness despite standard hormonal preparation. The clinical consequence is either repeated transfer cancellations (when the threshold is not reached and the clinical team defers rather than transfer into an inadequate lining) or repeated failed transfers in a thin lining that was judged "acceptable" but below optimal. Either way, the outcome is failed fertility treatment despite potentially good embryo quality.

What Is PRP and Why Might It Help?

Platelet-rich plasma is a preparation made from the patient's own blood. The blood is centrifuged to separate and concentrate the platelet fraction — producing a plasma with 3 to 5 times the normal platelet concentration. Platelets are not just involved in clotting; they contain dense granules loaded with growth factors including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and insulin-like growth factor (IGF).

These growth factors are potent stimulators of tissue repair, proliferation, and angiogenesis (new blood vessel formation). When delivered directly into the uterine cavity, the hypothesis is that they stimulate:

• Endometrial stem cell proliferation — promoting regrowth of the functional endometrial layer
• Angiogenesis — improving blood supply to the endometrium, a key determinant of lining development
• Reduced fibrous scar tissue in post-surgical thin endometria (Asherman's)

What Does the Evidence Show?

The evidence for intrauterine PRP is encouraging but not yet definitive. Key findings:

• A 2018 randomised controlled trial (Chang et al.) in women with thin endometrium (below 7 mm after standard oestrogen preparation) showed significantly greater endometrial thickness improvement in the PRP group versus controls (increase of 1.8 mm vs 0.4 mm), with significantly higher clinical pregnancy and ongoing pregnancy rates.
• Multiple prospective case series from Iran, China, and India consistently report endometrial thickness improvements of 1.5 to 3 mm in approximately 60 to 75% of treated women with refractory thin endometrium.
• A 2021 meta-analysis of available PRP studies concluded significant improvement in endometrial thickness and clinical pregnancy rates in thin endometrium cases, though noting the limitation of small study sizes.
• A 2023 RCT specifically in Asherman's syndrome patients post-adhesiolysis found significantly higher endometrial thickness and pregnancy rates in the PRP group compared to standard oestrogen alone.

The quality of evidence is Tier 2 — multiple controlled studies with consistent directional findings, but not yet the large multicentre RCT that would establish definitive clinical guidance. This is sufficient to justify selective use in patients with refractory thin endometrium who have exhausted standard options.

Who Is an Appropriate Candidate for Intrauterine PRP?

PRP is not the first-line treatment for thin endometrium — standard approaches should be optimised first:

• First: Maximise oestrogen dose and duration (oral, transdermal, or vaginal)
• Second: Add vaginal sildenafil and low-dose aspirin
• Third: Consider a natural cycle FET (which uses the corpus luteum's natural hormone production rather than exogenous oestrogen)
• If these fail: Hysteroscopy to exclude intrauterine adhesions; endometrial scratch; intrauterine G-CSF (granulocyte colony stimulating factor)
• PRP is appropriate after two or more failed preparation cycles with optimised standard treatment, where the endometrium consistently reaches below 7 mm despite maximised oestrogen therapy.

Specific situations where PRP may be particularly relevant:

• Post-Asherman's syndrome adhesiolysis — after surgical release of adhesions, PRP supports endometrial regrowth
• Radiation-damaged endometrium — where endometrial stem cells have been depleted by previous pelvic radiation
• Refractory thin endometrium after multiple failed standard cycles

The Procedure

Intrauterine PRP infusion is performed as an outpatient procedure:

• Blood is drawn from the patient (typically 20 to 30 ml)
• The sample is centrifuged twice to concentrate the platelet fraction
• The resulting PRP (approximately 3 to 5 ml) is transferred into a fine catheter and instilled into the uterine cavity through the cervix — a procedure similar to an embryo transfer, taking 5 to 10 minutes
• Mild cramping may be experienced; no anaesthesia is required
• The patient returns for endometrial thickness assessment after 48 to 72 hours

In most protocols, the PRP infusion is performed 48 hours before progesterone is started (for a frozen embryo transfer cycle), allowing time for the growth factors to act on the endometrium before the transfer window opens. Some protocols use two infusions 48 hours apart.

Frequently Asked Questions

Q1. Is PRP safe for intrauterine use?

Yes — intrauterine PRP is derived from the patient's own blood, so immunological reactions are not a concern. The procedure risk is essentially the same as any intrauterine catheter procedure — a small risk of infection (minimised by sterile technique) and the theoretical risk of any pelvic procedure. No serious adverse events have been reported in the published PRP series. It is one of the lowest-risk interventions available for refractory thin endometrium.

Q2. How quickly does the endometrium respond to PRP?

The majority of responses are detectable on ultrasound within 48 to 72 hours of the infusion. This rapid timeline reflects the direct growth factor stimulation of endometrial proliferation. In women who do respond, thickness improvements of 1.5 to 3 mm over the baseline are typical. Non-responders show little or no change.

Q3. If PRP does not work, what are the remaining options for thin endometrium?

If optimised oestrogen, sildenafil, aspirin, natural cycle FET, and PRP have all failed to produce an adequate endometrium, the clinical options narrow significantly. G-CSF (granulocyte colony stimulating factor) intrauterine infusion is another adjunct with some evidence. For women with radiation-induced thin endometrium who have not responded to any treatment, gestational surrogacy becomes the remaining option — where the embryo is transferred into a surrogate's receptive uterus. This conversation, though difficult, is part of compassionate and complete clinical care.